Effects of Doxorubicin on Extracellular Matrix Regulation in Primary Cardiac Fibroblasts from Mice

BMC Res Notes. 2023 Nov 16;16(1):340. doi: 10.1186/s13104-023-06621-7.

Abstract

Objective: Doxorubicin (DOX) is a highly effective chemotherapeutic used to treat many adult and pediatric cancers. However, its use is limited due to a dose-dependent cardiotoxicity, which can lead to lethal cardiomyopathy. In contrast to the extensive research efforts on toxic effects of DOX in cardiomyocytes, its effects and mechanisms on cardiac extracellular matrix (ECM) homeostasis and remodeling are poorly understood. In this study, we examined the potential effects of DOX on cardiac ECM to further our mechanistic understanding of DOX-induced cardiotoxicity.

Results: DOX-induced significant down-regulation of several ECM related genes in primary cardiac fibroblasts, including Adamts1, Adamts5, Col4a1, Col4a2, Col5a1, Fbln1, Lama2, Mmp11, Mmp14, Postn, and TGFβ. Quantitative proteomics analysis revealed significant global changes in the fibroblast proteome following DOX treatment. A pathway analysis using iPathwayGuide of the differentially expressed proteins revealed changes in a list of biological pathways that involve cell adhesion, cytotoxicity, and inflammation. An apparent increase in Picrosirius red staining indicated that DOX-induced an increase in collagen production in cardiac primary fibroblasts after 3-day treatment. No significant changes in collagen organization nor glycoprotein production were observed.

Keywords: Cardiac fibroblasts; Cardiotoxicity; Doxorubicin; Extracellular matrix; Proteomics.

MeSH terms

  • Animals
  • Apoptosis
  • Cardiotoxicity* / metabolism
  • Child
  • Collagen / metabolism
  • Collagen / pharmacology
  • Doxorubicin* / pharmacology
  • Extracellular Matrix / metabolism
  • Fibroblasts
  • Humans
  • Mice
  • Myocytes, Cardiac
  • Oxidative Stress

Substances

  • Doxorubicin
  • Collagen